MS-20 is under clinical development by Microbio and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MS-20’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MS-20 overview

MS-20 is under development for the treatment of non-small cell lung cancer and ulcerative colitis of IBD. It was under development of hepatocellular carcinoma, neutropenic fever in cancer patients undergoing chemotherapy and cachexia in liver cancer patients. The drug candidate is derived from the fermentation of organic, non-GM soybeans. It is developed using the proprietary fermentation platform. MS-20 has proven effect in enhancing intestinal beneficial bacteria. MS-20 is protected by a family of strategic international patents. It is administered through oral route as a solution.

Microbio overview

Microbio develops, manufactures and commercializes drugs in the areas of cancer, autoimmune and other metabolic diseases. It offers fermentation products, including Tien Chun Bao (TCB) oral solutions; herbal products, including LeeHerb series products, as well as organic foods, including vegetables, fruits, nuts, pastry, seasonings, organic meals and others. The company provides new medicines, anticancer medicines, medicines for hepatitis and rheumatoid arthritis, among others. Microbio is headquartered in Taipei, Taiwan.

For a complete picture of MS-20’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.